BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel) 2019;12:E114. [PMID: 31362406 DOI: 10.3390/ph12030114] [Cited by in Crossref: 113] [Cited by in F6Publishing: 117] [Article Influence: 37.7] [Reference Citation Analysis]
Number Citing Articles
1 Kanellopoulos P, Nock BA, Greifenstein L, Baum RP, Roesch F, Maina T. [68Ga]Ga-DATA5m-LM4, a PET Radiotracer in the Diagnosis of SST2R-Positive Tumors: Preclinical and First Clinical Results. IJMS 2022;23:14590. [DOI: 10.3390/ijms232314590] [Reference Citation Analysis]
2 Larenkov AA, Mitrofanov YA, Rakhimov MG. Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2022;12:455-467. [DOI: 10.30895/1991-2919-2022-12-4-455-467] [Reference Citation Analysis]
3 Puglioli S, Schmidt E, Pellegrino C, Prati L, Oehler S, De Luca R, Galbiati A, Comacchio C, Nadal L, Scheuermann J, Manz MG, Neri D, Cazzamalli S, Bassi G, Favalli N. Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation library. Chem 2022. [DOI: 10.1016/j.chempr.2022.10.006] [Reference Citation Analysis]
4 Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals 2022;15:1292. [DOI: 10.3390/ph15101292] [Reference Citation Analysis]
5 Elajami MK, Burton LP, Bahmad HF, Chaaya G, Schwartz M. Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma. Curr Oncol 2022;29:7552-7. [PMID: 36290871 DOI: 10.3390/curroncol29100594] [Reference Citation Analysis]
6 Kunert JP, Fischer S, Wurzer A, Wester HJ. Albumin-Mediated Size Exclusion Chromatography: The Apparent Molecular Weight of PSMA Radioligands as Novel Parameter to Estimate Their Blood Clearance Kinetics. Pharmaceuticals (Basel) 2022;15:1161. [PMID: 36145382 DOI: 10.3390/ph15091161] [Reference Citation Analysis]
7 Koustoulidou S, Handula M, de Ridder C, Stuurman D, Beekman S, de Jong M, Nonnekens J, Seimbille Y. Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors. Pharmaceuticals (Basel) 2022;15:1155. [PMID: 36145375 DOI: 10.3390/ph15091155] [Reference Citation Analysis]
8 Gu J, Wu Q, Zhang Q, You Q, Wang L. A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. Eur J Med Chem 2022;243:114742. [PMID: 36155354 DOI: 10.1016/j.ejmech.2022.114742] [Reference Citation Analysis]
9 Grzmil M, Boersema P, Sharma A, Blanc A, Imobersteg S, Pruschy M, Picotti P, Schibli R, Behe M. Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT). J Hematol Oncol 2022;15:123. [PMID: 36045419 DOI: 10.1186/s13045-022-01343-y] [Reference Citation Analysis]
10 Lynes J, Flores-milan G, Rubino S, Arrington J, Macaulay R, Liu JKC, Beer-furlan A, Tran ND, Vogelbaum MA, Etame AB. Molecular determinants of outcomes in meningiomas. Front Oncol 2022;12:962702. [DOI: 10.3389/fonc.2022.962702] [Reference Citation Analysis]
11 Lau J, Lee H, Rousseau J, Bénard F, Lin K. Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies. Molecules 2022;27:4959. [DOI: 10.3390/molecules27154959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide‒drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 de Aguiar Ferreira C, Heidari P, Ataeinia B, Sinevici N, Granito A, Kumar HM, Wehrenberg-klee E, Mahmood U. Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics 2022;14:1460. [DOI: 10.3390/pharmaceutics14071460] [Reference Citation Analysis]
14 Gilardoni E, Zana A, Galbiati A, Sturm T, Millul J, Cazzamalli S, Neri D, Stucchi R. Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule-Metal Conjugates. Anal Chem 2022. [PMID: 35820828 DOI: 10.1021/acs.analchem.2c01104] [Reference Citation Analysis]
15 Yang S, Banik N, Han B, Lee D, Park J. Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy. Pharmaceutics 2022;14:1378. [DOI: 10.3390/pharmaceutics14071378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Simón M, Jørgensen JT, Khare HA, Christensen C, Nielsen CH, Kjaer A. Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model. Pharmaceutics 2022;14:1284. [PMID: 35745856 DOI: 10.3390/pharmaceutics14061284] [Reference Citation Analysis]
17 Kumar S, Melek M, Rohl P. Case Report: Hypoglycemia Due to Metastatic Insulinoma in Insulin-Dependent Type 2 Diabetes Successfully Treated With 177 Lu-DOTATATE. Front Endocrinol 2022;13:906012. [DOI: 10.3389/fendo.2022.906012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Desai P, Rimal R, Sahnoun SEM, Mottaghy FM, Möller M, Morgenroth A, Singh S. Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers. Small. [DOI: 10.1002/smll.202200673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 2022;27:2259. [PMID: 35408658 DOI: 10.3390/molecules27072259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Muto Y, Okuma Y. Therapeutic options in thymomas and thymic carcinomas. Expert Rev Anticancer Ther 2022. [PMID: 35266421 DOI: 10.1080/14737140.2022.2052278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Gilardoni E, Zana A, Galbiati A, Sturm T, Millul J, Cazzamalli S, Neri D, Stucchi R. A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates.. [DOI: 10.1101/2022.03.04.483029] [Reference Citation Analysis]
22 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Alkassis S, Ali M, Awadelkarim AM, Saad E, Halboni A, Alhusain R, Kamatham S, Idris I. Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome. Cureus 2022. [DOI: 10.7759/cureus.22392] [Reference Citation Analysis]
24 Laudicella R, Comelli A, Liberini V, Vento A, Stefano A, Spataro A, Crocè L, Baldari S, Bambaci M, Deandreis D, Arico’ D, Ippolito M, Gaeta M, Alongi P, Minutoli F, Burger IA, Baldari S. [68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The “Theragnomics” Concept. Cancers 2022;14:984. [DOI: 10.3390/cancers14040984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Montella L, Ottaviano M, Morra R, Pietroluongo E, De Placido P, Tortora M, Sorrentino C, Facchini G, De Placido S, Giuliano M, Palmieri G. The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? Cancers (Basel) 2022;14:774. [PMID: 35159040 DOI: 10.3390/cancers14030774] [Reference Citation Analysis]
26 Naik M, Al-Nahhas A, Khan SR. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now. Cancers (Basel) 2022;14:761. [PMID: 35159027 DOI: 10.3390/cancers14030761] [Reference Citation Analysis]
27 Yan Y, Wang H, Zhao Y. Radiolabeled peptide probe for tumor imaging. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.02.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Griffiths GL, Vasquez C, Escorcia F, Clanton J, Lindenberg L, Mena E, Choyke PL. Translating a radiolabeled imaging agent to the clinic. Adv Drug Deliv Rev 2022;181:114086. [PMID: 34942275 DOI: 10.1016/j.addr.2021.114086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Hişir D, Ekinci M, İlem-özdemir D. HEDEFE YÖNELİK TEDAVİDE GÜNCEL YAKLAŞIMLAR: LUTESYUM-177 İLE İŞARETLİ RADYOFARMASÖTİKLER. Ankara Universitesi Eczacilik Fakultesi Dergisi 2022. [DOI: 10.33483/jfpau.1007773] [Reference Citation Analysis]
30 Silva F, D'Onofrio A, Mendes C, Pinto C, Marques A, Campello MPC, Oliveira MC, Raposinho P, Belchior A, Di Maria S, Marques F, Cruz C, Carvalho J, Paulo A. Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models. Int J Mol Sci 2022;23:617. [PMID: 35054798 DOI: 10.3390/ijms23020617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Mitra A, Lad S, Sahu S, Kulkarni S. A method to prevail false positive responses due to excess cations and viscous nature of Radiopharmaceuticals in Limulus Amebocyte Lysate Gel Clot test. Asia Ocean J Nucl Med Biol 2022;10:109-16. [PMID: 35800418 DOI: 10.22038/AOJNMB.2021.59607.1416] [Reference Citation Analysis]
32 Edelmann MR. Radiolabelling small and biomolecules for tracking and monitoring. RSC Adv 2022;12:32383-32400. [DOI: 10.1039/d2ra06236d] [Reference Citation Analysis]
33 Tng DJH, Chong LM, Chua MLK, Zhang Y, Yong K. Nanoparticles for Enhanced Radiotherapy and Imaging Applications. Nanomaterials for Cancer Detection Using Imaging Techniques and Their Clinical Applications 2022. [DOI: 10.1007/978-3-031-09636-5_2] [Reference Citation Analysis]
34 Benešová M, Reischl G. Production of radionuclides: Cyclotrons and reactors. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00003-x] [Reference Citation Analysis]
35 Kim H, Lee HY, Lee SH, Lee IS, Choi JY, Shim YM. Rarest of rare cases within the one thousand faces of atypical carcinoid: Pseudomesotheliomatous manifestation in a pregnant woman. Thorac Cancer 2021. [PMID: 34970830 DOI: 10.1111/1759-7714.14297] [Reference Citation Analysis]
36 Brandt F, Ullrich M, Laube M, Kopka K, Bachmann M, Löser R, Pietzsch J, Pietzsch HJ, van den Hoff J, Wodtke R. "Clickable" Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. J Med Chem 2021. [PMID: 34939412 DOI: 10.1021/acs.jmedchem.1c01791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Barca C, Griessinger CM, Faust A, Depke D, Essler M, Windhorst AD, Devoogdt N, Brindle KM, Schäfers M, Zinnhardt B, Jacobs AH. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. Pharmaceuticals (Basel) 2021;15:13. [PMID: 35056071 DOI: 10.3390/ph15010013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Diusenova S, Arkhipov S, Avdeev D, Dorovatovskii P, Khachatryan D, Lazarenko V, Medvedev M, Nikolaeva A, Ovchinnikov M, Sidorova M, Zubavichus Y. The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe. Crystals 2022;12:12. [DOI: 10.3390/cryst12010012] [Reference Citation Analysis]
39 Broqueza J, Prabaharan CB, Allen KJH, Jiao R, Fisher DR, Dickinson R, MacDonald-Dickinson V, Uppalapati M, Dadachova E. Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models. Pharmaceuticals (Basel) 2021;15:10. [PMID: 35056067 DOI: 10.3390/ph15010010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Deep K, Wanage G, Loharkar S, Das T, Basu S, Banerjee S. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-Labeled DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [177Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles. Cancer Biother Radiopharm 2021. [PMID: 34910891 DOI: 10.1089/cbr.2021.0340] [Reference Citation Analysis]
41 Da Silva I, Johnson TR, Mixdorf JC, Aluicio-Sarduy E, Barnhart TE, Nickles RJ, Engle JW, Ellison PA. A High Separation Factor for 165Er from Ho for Targeted Radionuclide Therapy. Molecules 2021;26:7513. [PMID: 34946596 DOI: 10.3390/molecules26247513] [Reference Citation Analysis]
42 Le Fur M, Fougère O, Lepareur N, Rousseaux O, Tripier R, Beyler M. Tuning the lipophilic nature of pyclen-based 90Y3+ radiopharmaceuticals for β-radiotherapy. Metallomics 2021;13:mfab070. [PMID: 34850060 DOI: 10.1093/mtomcs/mfab070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kossatz S, Beer AJ, Notni J. It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals. Cancers (Basel) 2021;13:5958. [PMID: 34885066 DOI: 10.3390/cancers13235958] [Reference Citation Analysis]
44 Bassi G, Favalli N, Pellegrino C, Onda Y, Scheuermann J, Cazzamalli S, Manz MG, Neri D. Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract. J Med Chem 2021;64:15799-809. [PMID: 34709820 DOI: 10.1021/acs.jmedchem.1c01103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Shalgunov V, Engudar G, Bohrmann L, Wharton L, Maskell K, Johann K, Barz M, Schaffer P, Herth MM, Radchenko V. Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225Ac, and beta-particle emitter, 177Lu. Nucl Med Biol 2021;104-105:11-21. [PMID: 34839209 DOI: 10.1016/j.nucmedbio.2021.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kang MS, Kong TWS, Khoo JYX, Loh TP. Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates. Chem Sci 2021;12:13613-47. [PMID: 34760149 DOI: 10.1039/d1sc02973h] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
47 Yordanova A, Ahmadzadehfar H. Combination Therapies with PRRT. Pharmaceuticals (Basel) 2021;14:1005. [PMID: 34681229 DOI: 10.3390/ph14101005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Foster A, Nigam S, Tatum DS, Raphael I, Xu J, Kumar R, Plakseychuk E, Latoche JD, Vincze S, Li B, Giri R, McCarl LH, Edinger R, Ak M, Peddagangireddy V, Foley LM, Hitchens TK, Colen RR, Pollack IF, Panigrahy A, Magda D, Anderson CJ, Edwards WB, Kohanbash G. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. EBioMedicine 2021;71:103571. [PMID: 34530385 DOI: 10.1016/j.ebiom.2021.103571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
49 Cassells I, Ahenkorah S, Burgoyne AR, Van de Voorde M, Deroose CM, Cardinaels T, Bormans G, Ooms M, Cleeren F. Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability. Front Med (Lausanne) 2021;8:675122. [PMID: 34504849 DOI: 10.3389/fmed.2021.675122] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Wu S, Helal-Neto E, Matos APDS, Jafari A, Kozempel J, Silva YJA, Serrano-Larrea C, Alves Junior S, Ricci-Junior E, Alexis F, Santos-Oliveira R. Radioactive polymeric nanoparticles for biomedical application. Drug Deliv 2020;27:1544-61. [PMID: 33118416 DOI: 10.1080/10717544.2020.1837296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
51 Siebinga H, de Wit-van der Veen BJ, Beijnen JH, Stokkel MPM, Dorlo TPC, Huitema ADR, Hendrikx JJMA. A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. EJNMMI Res 2021;11:73. [PMID: 34398356 DOI: 10.1186/s13550-021-00821-7] [Reference Citation Analysis]
52 O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am 2020;29:145-63. [PMID: 32151353 DOI: 10.1016/j.soc.2019.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci 2021:S0165-6147(21)00136-X. [PMID: 34334251 DOI: 10.1016/j.tips.2021.07.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
54 Chigoho DM, Bridoux J, Hernot S. Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals. Curr Opin Chem Biol 2021;63:219-28. [PMID: 34325089 DOI: 10.1016/j.cbpa.2021.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
55 Zaccagna F, Grist JT, Quartuccio N, Riemer F, Fraioli F, Caracò C, Halsey R, Aldalilah Y, Cunningham CH, Massoud TF, Aloj L, Gallagher FA. Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances. Eur J Radiol 2021;142:109842. [PMID: 34274843 DOI: 10.1016/j.ejrad.2021.109842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
56 Gilpin IMF, Ullrich M, Wünsche T, Zarschler K, Lebeda O, Pietzsch J, Pietzsch HJ, Walther M. Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics. ChemMedChem 2021;16:2645-9. [PMID: 33949125 DOI: 10.1002/cmdc.202100131] [Reference Citation Analysis]
57 Siikanen J, Jussing E, Milton S, Steiger C, Ulin J, Jonsson C, Samén E, Tran TA. Cyclotron-produced 68Ga from enriched 68Zn foils. Appl Radiat Isot 2021;176:109825. [PMID: 34157495 DOI: 10.1016/j.apradiso.2021.109825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
58 Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H, Ung COL. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model. Front Med (Lausanne) 2021;8:669509. [PMID: 34136505 DOI: 10.3389/fmed.2021.669509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
59 Asti M, D’ambrosio L, Di Iorio V, Ferrari M, Filice A, Gorgoni G, Maccauro M, Pettinato C, Stasi M, Zorz A. Methods for preparation and administration of lutetium-177 oxodotreotide 3.7 GBq: proceedings from an Italian advisory board. Clin Transl Imaging 2021;9:277-80. [DOI: 10.1007/s40336-021-00431-2] [Reference Citation Analysis]
60 Suman SK, Subramanian S, Mukherjee A. Combination radionuclide therapy: A new paradigm. Nucl Med Biol 2021;98-99:40-58. [PMID: 34029984 DOI: 10.1016/j.nucmedbio.2021.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
61 Damiana TST, Dalm SU. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. Pharmaceutics 2021;13:674. [PMID: 34067215 DOI: 10.3390/pharmaceutics13050674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, Yang K, Zhang X. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study. Front Pharmacol 2021;12:624534. [PMID: 33986664 DOI: 10.3389/fphar.2021.624534] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
63 Brossard C, Vlach M, Vène E, Ribault C, Dorcet V, Noiret N, Loyer P, Lepareur N, Cammas-Marion S. Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells. Nanomaterials (Basel) 2021;11:958. [PMID: 33918663 DOI: 10.3390/nano11040958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
64 Ludwig BS, Kessler H, Kossatz S, Reuning U. RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field. Cancers (Basel) 2021;13:1711. [PMID: 33916607 DOI: 10.3390/cancers13071711] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
65 Herrero Álvarez N, Bauer D, Hernández-Gil J, Lewis JS. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021. [PMID: 33792195 DOI: 10.1002/cmdc.202100135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
66 Miranda VM. Medicinal inorganic chemistry: an updated review on the status of metallodrugs and prominent metallodrug candidates. Reviews in Inorganic Chemistry 2021;0:000010151520200030. [DOI: 10.1515/revic-2020-0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
67 Anderson RC, Velez EM, Desai B, Jadvar H. Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors. Nucl Med Mol Imaging 2021;55:31-7. [PMID: 33643487 DOI: 10.1007/s13139-020-00677-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
68 Bandari RP, Carmack TL, Malhotra A, Watkinson L, Fergason Cantrell EA, Lewis MR, Smith CJ. Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA. J Med Chem 2021;64:2151-66. [PMID: 33534560 DOI: 10.1021/acs.jmedchem.0c01785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
69 Fu H, Du B, Chen Z, Li Y. Radiolabeled Peptides for SPECT and PET Imaging in the Detection of Breast Cancer: Preclinical and Clinical Perspectives. Curr Med Chem 2020;27:6987-7002. [PMID: 32003658 DOI: 10.2174/0929867327666200128110827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
70 Kang KW. Functional Imaging and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor. Korean J Pancreas Biliary Tract 2021;26:10-14. [DOI: 10.15279/kpba.2021.26.1.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Khan A, Dias F, Neekhra S, Singh B, Srivastava R. Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics. Front Chem 2020;8:631351. [PMID: 33585406 DOI: 10.3389/fchem.2020.631351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
72 Manabe Y, Shimoyama A, Kabayama K, Fukase K. Conjugation Strategies for Development of Bioactive Middle Molecules. Middle Molecular Strategy 2021. [DOI: 10.1007/978-981-16-2458-2_1] [Reference Citation Analysis]
73 Chin RI, Wu FS, Menda Y, Kim H. Radiopharmaceuticals for Neuroendocrine Tumors. Semin Radiat Oncol 2021;31:60-70. [PMID: 33246637 DOI: 10.1016/j.semradonc.2020.07.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
74 Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. Cancer Treat Rev 2021;93:102141. [PMID: 33418096 DOI: 10.1016/j.ctrv.2020.102141] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
75 Sowa Dumond AR, Scott PJ. Concepts and Issues for Therapeutic Radiopharmaceuticals. Handbook of Radiopharmaceuticals 2020. [DOI: 10.1002/9781119500575.ch2] [Reference Citation Analysis]
76 Kim YI. Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun 2021;42:451-8. [PMID: 33346603 DOI: 10.1097/MNM.0000000000001350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
77 Zhao R, Ploessl K, Zha Z, Choi S, Alexoff D, Zhu L, Kung HF. Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives. Mol Pharm 2020;17:4589-602. [PMID: 33108189 DOI: 10.1021/acs.molpharmaceut.0c00777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
78 Malo ME, Allen KJH, Jiao R, Frank C, Rickles D, Dadachova E. Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma. Int J Mol Sci 2020;21:E8721. [PMID: 33218169 DOI: 10.3390/ijms21228721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Redfern JS. Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands. PPIJ 2020;8:325-331. [DOI: 10.15406/ppij.2020.08.00313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Qin Y, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP, Grzmil M. Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy. Pharmaceutics 2020;12:E1088. [PMID: 33198403 DOI: 10.3390/pharmaceutics12111088] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
81 Si Y, Guan J, Xu Y, Chen K, Kim S, Zhou L, Jaskula-Sztul R, Liu XM. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics 2020;12:E1079. [PMID: 33187322 DOI: 10.3390/pharmaceutics12111079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
82 Shah JV, Gonda A, Pemmaraju R, Subash A, Bobadilla Mendez C, Berger M, Zhao X, He S, Riman RE, Tan MC, Pierce MC, Moghe PV, Ganapathy V. Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring. Front Mol Biosci 2020;7:569415. [PMID: 33134314 DOI: 10.3389/fmolb.2020.569415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
83 Mehrotra N, Kharbanda S, Singh H. Peptide-based combination nanoformulations for cancer therapy. Nanomedicine (Lond) 2020;15:2201-17. [PMID: 32914691 DOI: 10.2217/nnm-2020-0220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
84 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis]
85 Basu S, Parghane RV, Kamaldeep, Chakrabarty S. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine 2020;50:447-64. [DOI: 10.1053/j.semnuclmed.2020.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
86 Kunos CA, Rubinstein LV, Capala J, McDonald MA. Phase 0 Radiopharmaceutical-Agent Clinical Development. Front Oncol 2020;10:1310. [PMID: 33014772 DOI: 10.3389/fonc.2020.01310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Nizou G, Favaretto C, Borgna F, Grundler PV, Saffon-merceron N, Platas-iglesias C, Fougère O, Rousseaux O, van der Meulen NP, Müller C, Beyler M, Tripier R. Expanding the Scope of Pyclen-Picolinate Lanthanide Chelates to Potential Theranostic Applications. Inorg Chem 2020;59:11736-48. [DOI: 10.1021/acs.inorgchem.0c01664] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
88 Majkowska-Pilip A, Gawęda W, Żelechowska-Matysiak K, Wawrowicz K, Bilewicz A. Nanoparticles in Targeted Alpha Therapy. Nanomaterials (Basel) 2020;10:E1366. [PMID: 32668687 DOI: 10.3390/nano10071366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
89 Loveless CS, Blanco JR, Diehl GL, Elbahrawi RT, Carzaniga TS, Braccini S, Lapi SE. Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets. J Nucl Med 2020;62:131-6. [DOI: 10.2967/jnumed.120.242941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
90 Nardo L, Schmall JP, Werner TJ, Malogolowkin M, Badawi RD, Alavi A. Potential Roles of Total-Body PET/Computed Tomography in Pediatric Imaging. PET Clinics 2020;15:271-9. [DOI: 10.1016/j.cpet.2020.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
91 Lee DY, Kim YI. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis. Clin Nucl Med 2020;45:604-10. [PMID: 32520503 DOI: 10.1097/RLU.0000000000003110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
92 Li L, Kuo HT, Wang X, Merkens H, Colpo N, Radchenko V, Schaffer P, Lin KS, Bénard F, Orvig C. tBu4octapa-alkyl-NHS for metalloradiopeptide preparation. Dalton Trans 2020;49:7605-19. [PMID: 32459231 DOI: 10.1039/d0dt00845a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Cimini A, Ricci M, Chiaravalloti A, Filippi L, Schillaci O. Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors. Int J Mol Sci 2020;21:E3849. [PMID: 32481723 DOI: 10.3390/ijms21113849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
94 Vaghaiwalla T, Ruhle B, Memeh K, Angelos P, Kaplan E, Liao CY, Polite B, Keutgen X. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery 2021;169:162-7. [PMID: 32446596 DOI: 10.1016/j.surg.2020.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
95 Carter KP, Deblonde GJ, Lohrey TD, Bailey TA, An DD, Shield KM, Lukens WW, Abergel RJ. Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals. Commun Chem 2020;3. [DOI: 10.1038/s42004-020-0307-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
96 Manabe Y, Shimoyama A, Kabayama K, Fukase K. Middle Molecular and Conjugation Strategies for Development of Bioactive Middle Molecules. J Synth Org Chem Jpn 2020;78:527-537. [DOI: 10.5059/yukigoseikyokaishi.78.527] [Reference Citation Analysis]
97 Harris AG, Vinik AI, OʼDorisio TM, OʼDorisio MS. Radioligand Theranostics in the Management of Neuroendocrine Tumors. Pancreas 2020;49:599-603. [PMID: 32433395 DOI: 10.1097/MPA.0000000000001546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Zha Z, Wu Z, Choi SR, Ploessl K, Smith M, Alexoff D, Zhu L, Kung HF. A New [68Ga]Ga-HBED-CC-Bisphosphonate as a Bone Imaging Agent. Mol Pharm 2020;17:1674-84. [PMID: 32251600 DOI: 10.1021/acs.molpharmaceut.0c00103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
99 Allott L, Dubash S, Aboagye EO. [18F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide. Cancers (Basel) 2020;12:E865. [PMID: 32252406 DOI: 10.3390/cancers12040865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
100 Myers A, Chitwood H. Peptide Receptor Radionuclide Therapy: An Emerging Treatment for Gastrointestinal Neuroendocrine Tumors. CJON 2020;24:129-133. [DOI: 10.1188/20.cjon.129-133] [Reference Citation Analysis]
101 Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Theranostic approaches in nuclear medicine: current status and future prospects. Expert Rev Med Devices 2020;17:331-43. [PMID: 32157920 DOI: 10.1080/17434440.2020.1741348] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
102 Hennrich U, Benešová M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel) 2020;13:E38. [PMID: 32138377 DOI: 10.3390/ph13030038] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 23.5] [Reference Citation Analysis]
103 Pirovano G, Jannetti SA, Carter LM, Sadique A, Kossatz S, Guru N, Demétrio De Souza França P, Maeda M, Zeglis BM, Lewis JS, Humm JL, Reiner T. Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clin Cancer Res 2020;26:2871-81. [PMID: 32066626 DOI: 10.1158/1078-0432.CCR-19-2440] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 22.5] [Reference Citation Analysis]
104 Rondon A, Degoul F. Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy. Bioconjug Chem 2020;31:159-73. [PMID: 31855602 DOI: 10.1021/acs.bioconjchem.9b00761] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
105 Fricke U, Hein L, Schwabe U. Neue Arzneimittel 2019. Arzneiverordnungs-Report 2020 2020. [DOI: 10.1007/978-3-662-62168-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Abdullayeva L. VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review). Wrld Acd Sci 2019. [DOI: 10.3892/wasj.2019.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Si Y, Kim S, Guenter R, Ou J, Lu Y, Chen K, Zhang J, Whitt J, Carter AM, Bibb JA, Jaskula-sztul R, Markert JM, Zhou L, Chen H, “Margaret” Liu X. Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer Therapy.. [DOI: 10.1101/688184] [Reference Citation Analysis]